Skip to main content
CRSP
NASDAQ Life Sciences

CTX310 Cuts Triglycerides 63% at Day 30 in Severe Hypertriglyceridemia

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$50.42
Mkt Cap
$4.857B
52W Low
$44.12
52W High
$63.45
52W Position info
14% above low
Off High info
21% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CRSP is trading near its 52-week low of $44.12 (14% above the low).

Summary

A single course of CTX310 lowered mean triglycerides 63% and ANGPTL3 65% from baseline at Day 30 in 10 Phase 1b patients with severe hypertriglyceridemia, where median baseline triglycerides topped 1,000 mg/dL. No treatment-related serious adverse events were reported, and seven participants have reached at least 90 days of follow-up. The biomarker activity supports target engagement, but the cohort is tiny and the release offers no comparator, so durability and clinical outcomes are still unproven. This is the first hard efficacy readout on CTX310 in the severe-disease setting and comes days after the Q3 update showed CASGEVY revenue of $99M, up 30% quarter over quarter, against a $111.4M quarterly net loss. The company's $2.28B cash pile funds at least 24 months of operations, so this program has room to run. Watch for longer follow-up and any enrollment update from the ongoing U.S. and ex-U.S. Phase 1b trials.

At the time of this announcement, CRSP was trading at $50.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $44.12 to $63.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CRSP - Latest Insights

CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $51.06 info
Change: +$1.08 (+2%) info
Market Cap: $4.953B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $51.06 info
Change: +$2.05 (+4%) info
Market Cap: $4.953B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $51.06 info
Change: +$2.05 (+4%) info
Market Cap: $4.953B info
CRSP
Oct 19, 2026, 4:30 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $49.00
Real-time Price: $51.06 info
Change: +$2.06 (+4%) info
Market Cap: $4.953B info
CRSP
Aug 03, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $50.70
Real-time Price: $51.06 info
Change: +$0.360 (+0.71%) info
Market Cap: $4.953B info